A T Hesselink1, R Sahli2, J Berkhof3, P J F Snijders4, M L van der Salm1, D Agard4, M C G Bleeker4, D A M Heideman5. 1. Self-screen B.V., Amsterdam, The Netherlands. 2. Institute of Microbiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland. 3. Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands. 4. Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands. 5. Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: dam.heideman@vumc.nl.
Abstract
BACKGROUND: Anyplex™ II HPV HR Detection (Seegene, Seoul, Korea) is a multiplex real-time PCR using tagging oligonucleotide cleavage and extension (TOCE) technology for simultaneous detection and genotyping of 14 high-risk (HR) HPV types, including HPV16 and HPV18. OBJECTIVES: To evaluate whether the clinical performance and reproducibility of Anyplex™ II HPV HR Detection meet the international consensus guidelines for HPV test requirements for cervical cancer screening [1]. STUDY DESIGN: The clinical performance of Anyplex™ II HPV HR Detection for detecting cervical intraepithelial neoplasia grade 2 or worse (CIN2+) was determined relative to that of the reference assay, i.e., HR HPV GP5+/6+-PCR-EIA, by analysis of a total of 879 cervical liquid based cytology (LBC) specimens from a screening population, of which 60 were from women with CIN2+. The intra-laboratory reproducibility and inter-laboratory agreement were determined on 509 LBC samples, of which 172 were positive by the reference assay. RESULTS: Anyplex™ II HPV HR Detection showed a clinical sensitivity for CIN2+ of 98.3% (59/60; 95% CI: 89.1-99.8) and a clinical specificity for CIN2+ of 93.6% (764/816; 95% CI: 89.8-96.1). The clinical sensitivity and specificity were non-inferior to those of HR HPV GP5+/6+-PCR-EIA (non-inferiority score test: P=0.005 and P=0.023, respectively). Both intra-laboratory reproducibility (96.8%; 95% CI: 95.3-98.1; kappa value of 0.93) and inter-laboratory agreement (96.0%; 95% CI: 94.3-97.4; kappa value of 0.91) were high. CONCLUSIONS: Anyplex™ II HPV HR Detection performs clinically non-inferior to HR HPV GP5+/6+-PCR-EIA. Anyplex™ II HPV HR Detection complies with international consensus validation metrics for HPV DNA tests for cervical cancer screening [1].
BACKGROUND: Anyplex™ II HPV HR Detection (Seegene, Seoul, Korea) is a multiplex real-time PCR using tagging oligonucleotide cleavage and extension (TOCE) technology for simultaneous detection and genotyping of 14 high-risk (HR) HPV types, including HPV16 and HPV18. OBJECTIVES: To evaluate whether the clinical performance and reproducibility of Anyplex™ II HPV HR Detection meet the international consensus guidelines for HPV test requirements for cervical cancer screening [1]. STUDY DESIGN: The clinical performance of Anyplex™ II HPV HR Detection for detecting cervical intraepithelial neoplasia grade 2 or worse (CIN2+) was determined relative to that of the reference assay, i.e., HR HPV GP5+/6+-PCR-EIA, by analysis of a total of 879 cervical liquid based cytology (LBC) specimens from a screening population, of which 60 were from women with CIN2+. The intra-laboratory reproducibility and inter-laboratory agreement were determined on 509 LBC samples, of which 172 were positive by the reference assay. RESULTS: Anyplex™ II HPV HR Detection showed a clinical sensitivity for CIN2+ of 98.3% (59/60; 95% CI: 89.1-99.8) and a clinical specificity for CIN2+ of 93.6% (764/816; 95% CI: 89.8-96.1). The clinical sensitivity and specificity were non-inferior to those of HR HPV GP5+/6+-PCR-EIA (non-inferiority score test: P=0.005 and P=0.023, respectively). Both intra-laboratory reproducibility (96.8%; 95% CI: 95.3-98.1; kappa value of 0.93) and inter-laboratory agreement (96.0%; 95% CI: 94.3-97.4; kappa value of 0.91) were high. CONCLUSIONS: Anyplex™ II HPV HR Detection performs clinically non-inferior to HR HPV GP5+/6+-PCR-EIA. Anyplex™ II HPV HR Detection complies with international consensus validation metrics for HPV DNA tests for cervical cancer screening [1].
Authors: A M Cornall; M Poljak; S M Garland; S Phillips; J H Tan; D A Machalek; M A Quinn; S N Tabrizi Journal: Eur J Clin Microbiol Infect Dis Date: 2016-11-08 Impact factor: 3.267
Authors: François Coutlée; Alexandra de Pokomandy; Ann N Burchell; Mariam El-Zein; Marie-Hélène Mayrand; Sophie Rodrigues-Coutlée; Deborah Money; Émilie Comète; Elisabeth McClymont; Danielle Rouleau; Eduardo L Franco Journal: J Med Virol Date: 2022-01-28 Impact factor: 20.693
Authors: Alyssa M Cornall; Marin Poljak; Suzanne M Garland; Samuel Phillips; Dorothy A Machalek; Jeffrey H Tan; Michael A Quinn; Sepehr N Tabrizi Journal: Papillomavirus Res Date: 2017-10-18
Authors: Anna Gottschlich; Alvaro Rivera-Andrade; Edwin Grajeda; Christian Alvarez; Carlos Mendoza Montano; Rafael Meza Journal: J Glob Oncol Date: 2017-01-18
Authors: Marion Saville; Farhana Sultana; Michael J Malloy; Louiza S Velentzis; Michael Caruana; Ellen L O Ip; Marco H T Keung; Karen Canfell; Julia M L Brotherton; David Hawkes Journal: J Clin Microbiol Date: 2019-01-30 Impact factor: 5.948
Authors: Yung Taek Ouh; Ji Jeong Park; Minjoo Kang; Miseon Kim; Jae Yun Song; So Jin Shin; Seung Hyuk Shim; Heon Jong Yoo; Maria Lee; Sung Jong Lee; Whan Shin; Gun Oh Chong; Min Chul Choi; Chel Hun Choi; Kyung Jin Min Journal: J Korean Med Sci Date: 2021-06-21 Impact factor: 2.153
Authors: Iris Babion; Barbara C Snoek; Putri W Novianti; Annelieke Jaspers; Nienke van Trommel; Daniëlle A M Heideman; Chris J L M Meijer; Peter J F Snijders; Renske D M Steenbergen; Saskia M Wilting Journal: Clin Epigenetics Date: 2018-06-07 Impact factor: 6.551